First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) (HL-Russia-1)

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia

The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).

Study Overview

• Status: Recruiting
• Conditions: Hodgkin Lymphoma, Adult
• Intervention / Treatment: Drug: Doxorubicin; Drug: Bleomycin; Drug: Vinblastine; Drug: Dacarbazine; Drug: Doxorubicin; Drug: Dacarbazine; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Vincristine; Drug: Dexamethasone

Detailed Description

The study is devoted to patients affected with Hodgkin Lymphoma in Russia.

The study aims to assess the efficacy and safety of three different approaches to first line chemotherapy for classical Hodgkin Lymphoma (HL):

1. Early favourable (stages I-IIA without unfavorable risk factors). Patients will receive two courses of standard ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine). Those with a PET-2 (positron emission tomography) negative scan (Deauville Score 1-3) will proceed with radiotherapy on initially involved site (20 Gy). Those with a PET-2 Deauville score 4 will proceed with additional 2 ABVD courses. After that, those with a PET-4 negative scan (Deauville Score 1-3) will proceed with radiotherapy on initially involved site (30 Gy). In case of PET-4 positive scan after 4 ABVD cycles (Deauville score 4-5) patients will be planned to perform the biopsy and in case of positive results, proceed to high-dose chemotherapy with autologous stem cell transplantation (HDT with ASCT). In case of negative results of the biopsy, they will proceed with additional 2 ABVD courses and restage again. Those with a PET-6 negative scan (Deauville Score 1-3) will proceed with radiotherapy on initially involved site (30 Gy). In case of PET-6 positive scan (Deauville score 4-5) patients will be proceeded to HDT with ASCT.

   Those with a PET-2 Deauville score 5 after 2 ABVD courses will be planned to perform the biopsy and in case of positive results, proceed to HDT with ASCT. In case of negative results of the biopsy they will proceed with additional 2 ABVD courses and restage again. Those with a PET-4 negative scan (Deauville Score 1-3) will proceed with radiotherapy on initially involved site (30 Gy). In case of PET-4 positive scan (Deauville score 4-5) patients will be proceeded to HDT with ASCT.

2. Early unfavorable (stages IA-B, IIA bulky and/or extranodal lesions, patients younger 50 years). Patients will receive two courses of EACODD-14 (etoposide 100 mg/m2 days 1-3, doxorubicin 50 mg/m2 day 1, cyclophosphamide 650 mg/m2 day 1, vincristine 1,4 mg/m2 day 8, dacarbazine 375 mg/m2 day 1, dexamethasone 20 mg days 1-3; cycle is repeated every 14 days). Those with a PET-2 negative scan (Deauville Score 1-3) will be deescalated to 2 courses of AVD (Adriamycin, vinblastine, and dacarbazine) and consolidative radiotherapy on initially involved site (30 Gy). Those with a PET-2-positive scan (Deauville score 4-5) will proceed with additional 2 EACODD-14 courses. After that, those with a PET-4 negative scan (Deauville Score 1-3) will proceed with radiotherapy on initially involved site (30 Gy). In case of PET-4 positive scan after 4 EACODD-14 cycles (Deauville score 4-5) patients will proceed with additional 2 EACODD-14 courses. After that, those with a PET-6 negative scan (Deauville Score 1-3) will proceed with radiotherapy on initially involved site (30 Gy). In case of PET-6 positive scan (Deauville score 4-5) patients will be proceeded to HDT with ASCT.
3. Advanced stages (younger 50 years). Patients will receive two courses of EACODD-14. Those with a PET-2 negative scan (Deauville Score 1-3) will proceed with 4 additional courses of EACODD-14. After that, patients with residual tumor ˂ 4 cm, will stop the therapy and start the follow-up phase. Patients with residual tumor ≥ 4 cm, will undergo consolidative radiotherapy on residual tumor (30 Gy). Those with a PET-2-positive scan (Deauville score 4-5) will proceed with additional 4 additional courses of EACODD-14. After that, those with a PET-6 negative scan (Deauville Score 1-3) will proceed with radiotherapy on residual tumor ≥ 2,5 cm (30 Gy). In case of PET-6 positive scan (Deauville score 4-5) patients will be proceeded to HDT with ASCT.

• Study Type: Interventional
• Enrollment (Estimated): 300
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Vladislav Sarzhevskiy, PhD; Phone Number: +7-910-436-00-40; Email: vladsar100@gmail.com
• Study Contact Backup: Name: Nikita Mochkin, PhD; Phone Number: +7-910-456-87-06; Email: nickmed@yandex.ru

Study Locations

• India
  • OPD-81 Main building, Dr. E Borges Road, Parel 400012
    • Mumbai, OPD-81 Main building, Dr. E Borges Road, Parel 400012, India
      • Recruiting
      • Tata Memorial Hospital
      • Contact: Hasmukh Jain, Dr.; Phone Number: 7718982948 02224177018; Email: dr.hkjain@gmail.com
      • Contact: Lingaraj Nayak, Dr.; Phone Number: 7718982948 02224177018
      • Contact: Manju Sengar, Dr.
      • Contact: Bhausaheb Bagal, Dr.
      • Contact: Tanuja Shet, Dr.
      • Contact: Archi Agrawal, Dr.
      • Contact: Venkatesh Rangarajan, Dr.
      • Contact: Alok Shetty, Dr.
      • Contact: Hasmukh Jain, Dr.
• Russian Federation
  • Moscow, Russian Federation, 105203
    • Recruiting
    • The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation
    • Contact: Vladislav Sarzhevskiy, MD, PhD; Phone Number: +74956037217; Email: vladsar100@gmail.com
    • Contact: Nikita Mochkin, MD, PhD; Phone Number: +74956037217; Email: nickmed@yandex.ru

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 46 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Histologically confirmed classical HL
• Previously untreated disease
• Age 18-5 years
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2
• Adequate organ and marrow function as defined below: absolute neutrophil count >1,0 x109/L, platelets >75 x109/L
• Total bilirubin <2 mg/dl without a pattern consistent with Gilbert's syndrome
• Creatinine within normal institutional limits or creatinine clearance >50 mL/min/1.73 m2
• Females of childbearing must have a negative pregnancy test at medical supervision even if had been using effective contraception
• Life expectancy > 6 months
• Able to adhere to the study visit schedule and other protocol requirements
• Sign (or their legally acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
• Access to PET-CT (positron emission computed tomography) scans facilities

Exclusion Criteria:

• Nodular Lymphocyte Predominant HL
• Prior chemotherapy or radiation therapy
• Pregnant or lactating females
• Cardiac arrhythmia, conduction abnormalities, ischemic cardiopathy, left ventricular hypertrophy or left ventricular ejection fraction (LVEF) ≤50% at echocardiography.
• Abnormal QTc (corrected QT interval) interval prolonged (>450 msec in males; >470 msec in women)
• Uncontrolled infectious disease
• Human immunodeficiency virus (HIV) positivity or active infectious A, B or C hepatitis. HBsAg-negative patients with anti-HBc (hepatitis B core antigen) antibody and can be enrolled provided that Hepatitis B Virus (HBV)-DNA are negative and that antiviral treatment with nucleos(t)ide analogs is provided
• Uncompensated diabetes
• Refusal of adequate contraception
• Any medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Early favorable HL; HL without adverse prognostic factors	Drug: Doxorubicin; 25 mg/m2 i.v. day 1,15 for ABVD/AVD; Other Names: ABVD; Drug: Bleomycin; 10,000 units/m2 i.v. days 1,15 for ABVD; Other Names: ABVD; Drug: Vinblastine; 6 mg/m2 i.v. days 1,15 for ABVD/AVD; Other Names: ABVD; Drug: Dacarbazine; 375 mg/m2 i.v. days 1,15 for ABVD/AVD; Other Names: ABVD; Drug: Doxorubicin; 50 mg/m2 i.v. day 1 for EACODD-14; Other Names: EACODD-14; Drug: Dacarbazine; 375 mg/m2 i.v. day 1 for EACODD-14; Other Names: EACODD-14
Experimental: Early unfavorable HL; Early unfavorable (stages IA-B, IIA bulky and/or extranodal lesions, age less than 50 years)	Drug: Doxorubicin; 25 mg/m2 i.v. day 1,15 for ABVD/AVD; Other Names: ABVD; Drug: Vinblastine; 6 mg/m2 i.v. days 1,15 for ABVD/AVD; Other Names: ABVD; Drug: Dacarbazine; 375 mg/m2 i.v. days 1,15 for ABVD/AVD; Other Names: ABVD; Drug: Doxorubicin; 50 mg/m2 i.v. day 1 for EACODD-14; Other Names: EACODD-14; Drug: Dacarbazine; 375 mg/m2 i.v. day 1 for EACODD-14; Other Names: EACODD-14; Drug: Etoposide; 100 mg/m2 i.v. days 1-3; Other Names: EACODD-14; Drug: Cyclophosphamide; 650 mg/m2 i.v. day 1; Other Names: EACODD-14; Drug: Vincristine; 1,4 mg/m2 i.v. day 8; Other Names: EACODD-14; Drug: Dexamethasone; 20 mg i.v. days 1-3; Other Names: EACODD-14
Experimental: Advanced stages HL; (age less than 50 years)	Drug: Doxorubicin; 25 mg/m2 i.v. day 1,15 for ABVD/AVD; Other Names: ABVD; Drug: Dacarbazine; 375 mg/m2 i.v. days 1,15 for ABVD/AVD; Other Names: ABVD; Drug: Doxorubicin; 50 mg/m2 i.v. day 1 for EACODD-14; Other Names: EACODD-14; Drug: Dacarbazine; 375 mg/m2 i.v. day 1 for EACODD-14; Other Names: EACODD-14; Drug: Etoposide; 100 mg/m2 i.v. days 1-3; Other Names: EACODD-14; Drug: Cyclophosphamide; 650 mg/m2 i.v. day 1; Other Names: EACODD-14; Drug: Vincristine; 1,4 mg/m2 i.v. day 8; Other Names: EACODD-14; Drug: Dexamethasone; 20 mg i.v. days 1-3; Other Names: EACODD-14

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete remission rate (CR)	CR rate is defined as the proportion of patients achieving a CR after 3 months of chemotherapy (interim) and at the end of treatment	up to 6 months
Acute Toxicity	The severity of the toxicities will be classified according to definitions of Common Terminology Criteria for Adverse Event (CTCAE) version 4.3. It will be determined by the incidence of severe, life- threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events (Infusion-related reactions)	6 months
Late Toxicity	The severity of the toxicities will be classified according to definitions of Common Terminology Criteria for Adverse Event (CTCAE) version 4.3. It will be determined by the incidence of severe, life- threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events (Infusion-related reactions)	5 years
Event-Free Survival (EFS)	EFS will be measured from the time from entry onto a study to any treatment failure including disease progression, or discontinuation of treatment for any reason (e.g., disease progression, toxicity, patient preference, initiation of new treatment lacking documented progression, or death)	5 years
Disease free survival (DFS)	DFS will be measured from the time of occurrence of disease-free state or attainment of a CR to disease recurrence or death as a result of lymphoma or acute toxicity of treatment	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	OS is defined as the time from entry onto the clinical trial until death as a result of any cause	5 years

Collaborators and Investigators

• Sponsor: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
• Investigators: Principal Investigator: Vladislav Sarzhevskiy, PhD, State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2020
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: November 16, 2020
• First Submitted That Met QC Criteria: November 16, 2020
• First Posted (Actual): November 20, 2020

Study Record Updates

• Last Update Posted (Actual): September 27, 2024
• Last Update Submitted That Met QC Criteria: September 25, 2024
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Keywords: EACODD-14
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma; Hodgkin Disease; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antibiotics, Antineoplastic; Dexamethasone; Cyclophosphamide; Etoposide; Doxorubicin; Liposomal doxorubicin; Vincristine; Dacarbazine; Bleomycin; Vinblastine
• Other Study ID Numbers: HL-Russia-1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No